LAUSR

Since 1941, when Huggins and Hodges reported that testosterone drives prostate cancer (PCa) growth [1], androgens have been considered as fuel for the disease, and androgen ablation is therefore a cornerstone in the treatment of advanced PCa. As a result, many PCa survivors experience treatment-related hypogonadism, manifesting, for example, as fatigue, decreased libido, emotional changes, and overall low quality of life. Although it is widely accepted that testosterone replacement may mitigate these symptoms, there is a general reluctance to prescribe testosterone for fear of stimulating PCa progression. It is also assumed that high testosterone over a lifetime increases the risk of PCa. However, two meta-analyses